Cemiplimab is a PD-1 inhibitor approved for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not suitable for curative surgery or curative radiotherapy.

How to Purchase Cemiplimab

Overseas Purchase

Patients may choose to consult and purchase cemiplimab at hospital pharmacies or authorized pharmacies in countries or regions where the drug has been launched.

Since drug prices may be affected by factors such as regional differences and exchange rate fluctuations, patients need to make a budget and plan in advance before purchasing.

Purchase via Medical Service Institutions

Patients may consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions can usually provide legal import channels and offer professional consultation and guidance.

Precautions for Purchasing Cemiplimab

Strict Medical Evaluation

A comprehensive evaluation by a professional doctor is mandatory before use.

According to FDA-approved information, this drug is indicated for specific types of CSCC patients. It is necessary to confirm that the patient meets the indications: patients with metastatic CSCC or locally advanced CSCC who are not suitable for curative surgery or radiotherapy.

Confirmation of Medication Regimen

The standard recommended dose is 350 mg, administered as an intravenous infusion once every 3 weeks, with each infusion lasting 30 minutes.

Before purchasing, the specific medication regimen formulated by the doctor (including dose, administration interval, etc.) should be confirmed.

Preparation for Adverse Reaction Monitoring

Cemiplimab may cause immune-related adverse reactions. Before purchasing, patients should understand these risks and make preparations for monitoring.

Common adverse reactions include fatigue (29%), rash (25%), and diarrhea (22%). Severe adverse reactions include immune-mediated pneumonitis, colitis, hepatitis, and endocrine disorders, which require close monitoring.

Precautions for Special Populations

The drug is contraindicated in pregnant women, as it may cause fetal harm.

Women of childbearing age should use effective contraceptive measures during treatment and for at least 4 months after the last dose.

Lactating women should discontinue breastfeeding during treatment and for 4 months after the last dose.

Methods to Identify Authenticity of Cemiplimab

Package Inspection

Authentic LIBTAYO (brand name of cemiplimab) is supplied as single-dose vials in two strengths: 350 mg/7 mL (50 mg/mL) and 250 mg/5 mL (50 mg/mL).

The package should be intact and undamaged, with a formal drug approval number and production batch number.

The solution should be a clear to slightly opalescent liquid, colorless to pale yellow, and may contain trace amounts of translucent to white particles.

Label Information Verification

Drug brand name (LIBTAYO) and generic name (cemiplimab-rwlc).

Strength and concentration (e.g., 350 mg/7 mL).

Storage conditions (refrigerated at 2°C to 8°C).

Manufacturer information (Regeneron Pharmaceuticals, Inc.).

Approval number.

Production batch number and expiration date.

Drug Property Inspection

The solution should be clear to slightly opalescent, colorless to pale yellow.

It may contain trace amounts of translucent to white particles.

If the solution is turbid, discolored, or contains foreign matter other than those mentioned above, it should be discarded and not used.